Global .2015 .Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2013. Available from: www. com [Last accessed on 15 Jan, : .
.2013 .Chronic obstructive pulmonary disease. Indian J Med Res, 137 : 251-69.
. .. [Last accessed on 2015 Jan, 15 : .
Kim ,Lee SW .2014 .Health care use and economic burden of patients with diagnosed chronic obstructive pulmonary disease in Korea. Int J Tuberc Lung Dis, 18 : 737-43.
Heart National . .‑chart‑book. htm; 2012. [Last accessed on 2015 Jan, 15 : .
.2008 .Screening for chronic obstructive pulmonary disease using spirometr y: U. S. preventive Ser vices task Force recommendation statement. Ann Intern Med, 148 : 529-34.
.2005 .Standardisation of lung function testing interpretative strategies for lung function tests. Eur Respir J, 26 : 948-68.
Balasubramanian ,Radhika N .2014 .The crave of fixed dose combination in Indian market. 2015 Jan, 15 : 106-10.
Comfort Christopher . .The COPD drug market will become more fractured as several new agents reach the market and erode the dominance of the current market leaders. [Last accessed on 2015 Jan, 15 : .
.2013 .Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir Res, 14 : 49.
Cazzola ,di Marco .2004 .The functional impact of adding salmeterol and tiotropium in patients with stable COPD. Respir Med, 98 : 1214-21.
Vogelmeier ,Formoterol .2008 .and combination therapy with tiotropium in patients with COPD: A 6‑month study. Respir Med, 102 : 1511-20.
Z ,SA .2010 .A preliminary randomized open labeled comparative analysis of efficacy and safety of inhaled Tiotropium and Tiotropium plus Formoterol in COPD. php?volume=12 and issueno=1 [Last accessed on 2015 Jan, 15 : 27-30.
.2011 .Triple inhalers for obstructive airways disease: Will they be useful?. Expert Rev Respir Med, 5 : 297-300.
Celik ,Beder .1999 .Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo‑controlled comparison of onset and duration of action. Respiration, 66 : 434-9.
Casaburi A .2002 .A long‑term evaluation of once‑daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J, 19 : 217-24.
Thorn ,Swensen A,Holguin A .2008 .Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J, 32 : 962-9.
Borg .1982 .Psychological basis of perceived exertion. Med Sci Sports Exer, 14 : 377-87.
Postma DS,De Vries DS .1985 .Influence of the parasympathetic and sympathetic nervous system on nocturnal bronchial obstruction. Clin Sci (Lond), 69 : 251-8.
N ,Green N,Y N .2013 .Dual bronchodilation with QVA149 versus single bronchodilator therapy: The SHINE study. Eur Respir J, 42 : 1484-94.
Wedzicha JA,Decramer M,Ficker JH,Niewoehner DE,SandstroANm T,Taylor AF .2013 .Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): A randomised, double‑blind, parallel‑group study. Lancet Respir Med, 1 : 199-209.